FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Basil Rigas

Research Profile

Chemicals & Drugs

Disorders

Colonic Neoplasms

Living Beings

Mouse

Anatomy

Physiology

Procedures

Xenograft Model Antitumor Assays

Co-author Network

Publications

TOP 3
George Mattheolabakis; Nengtai Ouyang; Ka Wing Cheng; Liqun Huang; Gerardo G Mackenzie; Basil Rigas
Topically Applied Phospho-Sulindac Hydrogel is Efficacious and Safe in the Treatment of Experimental Arthritis in Rats.
Gang Xie; Dingying Zhou; Ka-Wing Cheng; Chi C Wong; Basil Rigas
Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans.
Dingying Zhou; Chi C Wong; Ninche Alston; Liqun Huang; Gerardo G Mackenzie; Ting Nie; Nengtai Ouyang; Ioannis Papayannis; Basil Rigas
The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Basil Rigas (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: George Mattheolabakis; Nengtai Ouyang; Ka Wing Cheng; Liqun Huang; Gerardo G Mackenzie; Basil Rigas
Topically Applied Phospho-Sulindac Hydrogel is Efficacious and Safe in the Treatment of Experimental Arthritis in Rats.
Pharmaceutical research 2013;30(6):1471-82.
2013: Gang Xie; Dingying Zhou; Ka-Wing Cheng; Chi C Wong; Basil Rigas
Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans.
Biochemical pharmacology 2013;85(8):1195-202.
2013: Dingying Zhou; Chi C Wong; Ninche Alston; Liqun Huang; Gerardo G Mackenzie; Ting Nie; Nengtai Ouyang; Ioannis Papayannis; Basil Rigas
The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies.
Carcinogenesis 2013;34(4):943-51.
2013: Tatsiana Mironava; Miriam H Rafailovich; Marcia Simon; Basil Rigas
Platinum folate nanoparticles toxicity: cancer vs. normal cells.
Toxicology in vitro : an international journal published in association with BIBRA 2013;27(2):882-9.
2013: Gerardo G Mackenzie; George Mattheolabakis; Nengtai Ouyang; Ninche Alston; Panayiotis P Constantinides; Liqun Huang; Kvetoslava Vrankova; Basil Rigas
Targeting Mitochondrial STAT3 with the Novel Phospho-Valproic Acid (MDC-1112) Inhibits Pancreatic Cancer Growth in Mice.
PloS one 2013;8(5):e61532.
2012: Gang Xie; Chi C Wong; Ka-Wing Cheng; Panayiotis P Constantinides; Liqun Huang; Basil Rigas
In vitro and in vivo metabolic studies of phospho-aspirin (MDC-22).
Pharmaceutical research 2012;29(12):3292-301.
2012: Rongrong Zhu; Yu Sun; Kveta Vrankova; Gang Xie; Ka-Wing Cheng; Panayiotis P Constantinides; Liqun Huang; Gerardo Mackenzie; Basil Rigas
Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles.
Pharmaceutical research 2012;29(11):3090-101.
2012: George Mattheolabakis; Basil Rigas; Panayiotis P Constantinides
Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives.
Nanomedicine (London, England) 2012;7(10):1577-90.
2012: Caihua Zhu; Yu Sun; Ka-Wing Cheng; Panayiotis Constantinides; Liqun Huang; Nengtai Ouyang; Basil Rigas
Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts.
Stem cells (Dayton, Ohio) 2012;30(10):2065-75.
2012: Gang Xie; Chi C Wong; Ka-Wing Cheng; Panayiotis P Constantinides; Liqun Huang; Basil Rigas
Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety.
British journal of pharmacology 2012;167(1):222-32.
2012: C C Wong; Ka-Wing Cheng; Basil Rigas
Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents.
The Journal of pharmacology and experimental therapeutics 2012;341(3):572-8.
2012: T Nie; N Alston; P Aro; P P Constantinides; C C Wong; Basil Rigas
Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: anti-cancer activity in vitro and in vivo.
British journal of pharmacology 2012;166(3):991-1001.
2012: George Mattheolabakis; Ting Nie; Panayiotis P Constantinides; Basil Rigas
Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC-917): preparation, characterization, and in vitro/in vivo evaluation.
Pharmaceutical research 2012;29(6):1435-43.
2012: G Xie; C Zhu; P P Constantinides; G G Mackenzie; O T Murray; N Alston; L Huang; Levy Kopelovich; T Nie; Nengtai Ouyang; Y Sun; Basil Rigas
The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine.
British journal of pharmacology 2012;165(7):2152-66.
2012: Chi C Wong; Gang Xie; Dingying Zhou; Cai-Hua Zhu; Ka-Wing Cheng; Panayiotis P Constantinides; Basil Rigas
Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity.
The Journal of pharmacology and experimental therapeutics 2012;340(2):422-32.
2012: Nengtai Ouyang; Robert J Richards; Mae F Go; Ting Nie; Dingying Zhou; Caihua Zhu; Basil Rigas
MC-12, an annexin A1-based peptide, is effective in the treatment of experimental colitis.
PloS one 2012;7(7):e41585.
2012: Yu Sun; Kvetoslava Vrankova; Leahana M Rowehl; Liqun Huang; Despina Komninou; Gerardo G Mackenzie; Basil Rigas
Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system.
Breast cancer research : BCR 2012;14(1):R20.
2011: Gerardo G Mackenzie; Nengtai Ouyang; Liqun Huang; Despina Komninou; Levy Kopelovich; Yu Sun; Kvetoslava Vrankova; Gang Xie; Basil Rigas
Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
Cancer prevention research (Philadelphia, Pa.) 2011;4(7):1052-60.
2011: Jennie L Williams; Ping Ji; Nengtai Ouyang; Levy Kopelovich; Basil Rigas
Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: Relevance to its mechanism of action.
Experimental cell research 2011;317(10):1359-67.
2011: Gang Xie; Yu Sun; Ting Nie; Gerardo G Mackenzie; Liqun Huang; Levy Kopelovich; Despina Komninou; Basil Rigas
Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models.
The Journal of pharmacology and experimental therapeutics 2011;337(3):876-86.
2011: L Huang; Gg Mackenzie; Nengtai Ouyang; Y Sun; G Xie; Francis Johnson; D Komninou; Basil Rigas
The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats.
British journal of pharmacology 2011;162(7):1521-33.
2010: Liqun Huang; Caihua Zhu; Yu Sun; Gang Xie; Gerardo G Mackenzie; George Qiao; Despina Komninou; Basil Rigas
Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect.
Carcinogenesis 2010;31(11):1982-90.
2010: Gerardo G Mackenzie; Yu Sun; Liqun Huang; Gang Xie; Nengtai Ouyang; Ramesh C Gupta; Francis Johnson; Despina Komninou; Levy Kopelovich; Basil Rigas
Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.
Gastroenterology 2010;139(4):1320-32.
2009: Amy Hua; Gerardo G Mackenzie; Basil Rigas
The differential cell signaling effects of two positional isomers of the anticancer NO-donating aspirin.
International journal of oncology 2009;35(4):837-44.
2009: Wenping Zhao; Gerardo G Mackenzie; Onika T Murray; Zhiquan Zhang; Basil Rigas
Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect.
Carcinogenesis 2009;30(3):512-9.
2009: Yu Sun; Jie Chen; Basil Rigas
Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death.
Carcinogenesis 2009;30(1):93-100.
2008: Chinthalapally V Rao; Stancy Joseph; Li Gao; Jagan M R Patlolla; Chang-In Choi; Levy Kopelovich; Vernon E Steele; Basil Rigas
Pharmacokinetic and pharmacodynamic study of NO-donating aspirin in F344 rats.
International journal of oncology 2008;33(4):799-805.
2008: Yantian Wang; Yanxiu Zhou; Jonathan C Sokolov; Basil Rigas; kalle levon; Miriam H Rafailovich
A potentiometric protein sensor built with surface molecular imprinting method.
Biosensors & bioelectronics 2008;24(1):162-6.
2008: Nengtai Ouyang; Jennie L Williams; Basil Rigas
NO-donating aspirin inhibits angiogenesis by suppressing VEGF expression in HT-29 human colon cancer mouse xenografts.
Carcinogenesis 2008;29(9):1794-8.
2008: Basil Rigas; Jennie L Williams
NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action.
Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society 2008;19(2):199-204.
2008: Jennie L Williams; Ping Ji; Nengtai Ouyang; Xiaoping Liu; Basil Rigas
NO-donating aspirin inhibits the activation of NF-kappaB in human cancer cell lines and Min mice.
Carcinogenesis 2008;29(2):390-7.
2008: Basil Rigas; Chinthalapally V Rao; Robert Cooney; Shivendra Singh
Food components, alternative medicine, and cancer: progress and promise.
Nutrition and cancer 2008;60 Suppl 1():1.
2008: Gerardo G Mackenzie; Shaheen Rasheed; William Wertheim; Basil Rigas
NO-Donating NSAIDs, PPARdelta, and Cancer: Does PPARdelta Contribute to Colon Carcinogenesis?
PPAR research 2008;2008():919572.
2007: Khosrow Kashfi; Basil Rigas
The mechanism of action of nitric oxide-donating aspirin.
Biochemical and biophysical research communications 2007;358(4):1096-101.
2007: Basil Rigas
The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia.
Current opinion in gastroenterology 2007;23(1):55-9.
2006: Chinthalapally V Rao; Bandaru S Reddy; Vernon E Steele; C-X Wang; Xiaoping Liu; Nengtai Ouyang; Jagan M R Patlolla; Barbara Simi; Levy Kopelovich; Basil Rigas
Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets.
Molecular cancer therapeutics 2006;5(6):1530-8.
2006: Nengtai Ouyang; Jennie L Williams; George J Tsioulias; Jianjun Gao; Michael J Iatropoulos; Levy Kopelovich; Khosrow Kashfi; Basil Rigas
Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model.
Cancer research 2006;66(8):4503-11.
2006: Jianjun Gao; Khosrow Kashfi; Xiaoping Liu; Basil Rigas
NO-donating aspirin induces phase II enzymes in vitro and in vivo.
Carcinogenesis 2006;27(4):803-10.
2006: Nengtai Ouyang; Jennie L Williams; Basil Rigas
NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)delta expression in APC(min/+) mice proportionally to their tumor inhibitory effect: Implications for the role of PPARdelta in carcinogenesis.
Carcinogenesis 2006;27(2):232-9.
2006: Thomas R Hundley; Basil Rigas
Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation.
The Journal of pharmacology and experimental therapeutics 2006;316(1):25-34.
2005: Jianjun Gao; Xiaoping Liu; Basil Rigas
Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(47):17207-12.
2005: Joshua Muscat; Anne-Marie Dyer; Raphael E Rosenbaum; Basil Rigas
Nitric oxide-releasing medications and colorectal cancer risk: the framingham study.
Anticancer research 2005;25(6C):4471-4.
2005: Adam Spiegel; Thomas R Hundley; Jie Chen; Jianjun Gao; Nengtai Ouyang; Xiaoping Liu; Mae F Go; George J Tsioulias; Khosrow Kashfi; Basil Rigas
NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells.
Biochemical pharmacology 2005;70(7):993-1000.
2005: Khosrow Kashfi; Basil Rigas
Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
Biochemical pharmacology 2005;70(7):969-86.
2005: Khosrow Kashfi; Basil Rigas
Is COX-2 a 'collateral' target in cancer prevention?
Biochemical Society transactions 2005;33(Pt 4):724-7.
2005: Khosrow Kashfi; Basil Rigas
Molecular targets of nitric-oxide-donating aspirin in cancer.
Biochemical Society transactions 2005;33(Pt 4):701-4.
2005: Basil Rigas; Khosrow Kashfi
Cancer prevention: a new era beyond cyclooxygenase-2.
The Journal of pharmacology and experimental therapeutics 2005;314(1):1-8.
2005: Khosrow Kashfi; Simona Borgo; Jennie L Williams; Jie Chen; Jianjun Gao; Athanasios Glekas; Francesca Benedini; Piero Del Soldato; Basil Rigas
Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo.
The Journal of pharmacology and experimental therapeutics 2005;312(3):978-88.
2005: Jianjun Gao; Khosrow Kashfi; Basil Rigas
In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism.
The Journal of pharmacology and experimental therapeutics 2005;312(3):989-97.
2005: Niharika Nath; Georges Labaze; Basil Rigas; Khosrow Kashfi
NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates beta-catenin expression.
Biochemical and biophysical research communications 2005;326(1):93-9.
2004: Basil Rigas; Khosrow Kashfi
Nitric-oxide-donating NSAIDs as agents for cancer prevention.
Trends in molecular medicine 2004;10(7):324-30.
2004: Raymond K Yeh; Jie Chen; Jennie L Williams; Mehdi Baluch; Thomas R Hundley; Raphael E Rosenbaum; Srinivas Kalala; Frank Traganos; Francesca Benardini; Piero Del Soldato; Khosrow Kashfi; Basil Rigas
NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property?
Biochemical pharmacology 2004;67(12):2197-205.
2004: Jennie L Williams; Khosrow Kashfi; Nengtai Ouyang; Piero Del Soldato; Levy Kopelovich; Basil Rigas
NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice.
Biochemical and biophysical research communications 2004;313(3):784-8.
2003: Jennie L Williams; Niharika Nath; Jie Chen; Thomas R Hundley; Jianjun Gao; Levy Kopelovich; Khosrow Kashfi; Basil Rigas
Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention.
Cancer research 2003;63(22):7613-8.
2003: Niharika Nath; Khosrow Kashfi; Jie Chen; Basil Rigas
Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(22):12584-9.
2002: Khosrow Kashfi; Yassir Ryan; Leon L Qiao; Jennie L Williams; Jie Chen; Piero Del Soldato; Frank Traganos; Basil Rigas; Yassir Ryann
Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect.
The Journal of pharmacology and experimental therapeutics 2002;303(3):1273-82.
2002: Chatargy S Kaza; Basil Rigas
Rapid placement of the Sengstaken-Blakemore tube using a guidewire.
Journal of clinical gastroenterology 2002;34(3):282.
2002: Chatargy S Kaza; Khosrow Kashfi; Basil Rigas
Colon cancer prevention with NO-releasing NSAIDs.
Prostaglandins & other lipid mediators 2002;67(2):107-20.
2001: Basil Rigas; Simona Borgo; A Elhosseiny; Vassilios Balatsos; Zisoula Manika; H Shinya; N Kurihara; M Go; M Lipkin
Decreased expression of DNA-dependent protein kinase, a DNA repair protein, during human colon carcinogenesis.
Cancer research 2001;61(23):8381-4.
2001: Jennie L Williams; Simona Borgo; I Hasan; E Castillo; F Traganos; Basil Rigas
Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention.
Cancer research 2001;61(8):3285-9.
2001: G Merritt; E T Aliprandis; F Prada; Basil Rigas; Khosrow Kashfi
The retinoid fenretinide inhibits proliferation and downregulates cyclooxygenase-2 gene expression in human colon adenocarcinoma cell lines.
Cancer letters 2001;164(1):15-23.
1997: E T Aliprandis; G Merritt; F Prada; Basil Rigas; Khosrow Kashfi
Fenretinide inhibits phorbol ester-induced cyclooxygenase-2 expression in human colon adenocarcinoma cells.
Biochemical Society transactions 1997;25(3):457S.